Sickle cell disease in childhood: from newborn screening through transition to adult medical care.
Charles T Quinn
https://pubmed.ncbi.nlm.nih.gov/24237976/Actively Recruiting
Led by Yves Pastore · Updated on 2026-08-21
29
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying patients with sickle cell disease to find out if monitoring hydroxyurea dosage using pharmacokinetic testing can help reach the maximum tolerated dose faster compared to standard bloodwork monitoring. The study includes children and adolescents aged 6 months to 18 years with specific sickle cell genotypes. Participants are divided into groups to compare different ways of adjusting hydroxyurea dosage over 12 months. Participants are randomized into three groups Group A will have their hydroxyurea dose adjusted based on pharmacokinetic results, Group B will have dose adjustments based on standard bloodwork follow-up, and Group C includes patients already on hydroxyurea for at least 12 months who will undergo a one-time pharmacokinetic test. The study follows participants for up to 12 months to evaluate dose adjustments and drug levels. During the study, participants will have pharmacokinetic blood samples collected at different times to monitor hydroxyurea levels and adjustments. Researchers will measure the time to reach the maximum tolerated dose, fetal hemoglobin levels, and safety through adverse event tracking. The primary outcome is the evaluation of hydroxyurea pharmacokinetics at 6 months between the groups, with further follow-up assessments up to 12 months.
CONDITIONS
Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
Y
Yves Pastore, MD
B
Bianka Courcelle, Research nurse, RN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Yves Pastore
Lead Sponsor
St. Justine's Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive hydroxyurea and have their dosage adjusted either by pharmacokinetic testing results or standard bloodwork over 12 months. Group C participants undergo a one-time pharmacokinetic test after stable treatment.
Multiple visits over 12 months for dosage adjustments and blood sample collections
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Charles T Quinn
https://pubmed.ncbi.nlm.nih.gov/24237976/Min Dong, Patrick T McGann
https://pubmed.ncbi.nlm.nih.gov/32869281/Sètondji Cocou Modeste Alexandre Yahouédéhou, Elisângela Vitória Adorno, Caroline Conceição da Guarda...
https://pubmed.ncbi.nlm.nih.gov/30206297/Anu Marahatta, Russell E Ware
https://pubmed.ncbi.nlm.nih.gov/28847416/Xin Hai, Meihua Guo, Chunlu Gao...
https://pubmed.ncbi.nlm.nih.gov/28131939/Simon Pleasants
https://pubmed.ncbi.nlm.nih.gov/25390139/Patrick T McGann, Omar Niss, Min Dong...
https://pubmed.ncbi.nlm.nih.gov/31106898/Courtney D Thornburg, Beatrice A Files, Zhaoyu Luo...
https://pubmed.ncbi.nlm.nih.gov/22915643/Jeffrey A Switzer, David C Hess, Fenwick T Nichols...
https://pubmed.ncbi.nlm.nih.gov/16713922/Luis A Verduzco, David G Nathan
https://pubmed.ncbi.nlm.nih.gov/19797523/Yves Pastore
Lead Sponsor
St. Justine's Hospital
Collaborating Sponsor